Why Oscar Health, Inc. (OSCR) stock moved
Why Oscar Health, Inc. (OSCR) fell 7.6% today, November 18, 2026
Oscar Health, Inc. (OSCR) fell 7.6% on November 18, 2026, closing at $27.57 versus $29.84 the prior session (close-to-close, from daily closes). The pullback followed a steep year-to-date run-up of roughly 95%–108% and occurred despite no major negative company announcement on the day itself. Profit-taking appears to have intensified after the stock slipped below its 50-day moving average earlier in November, with traders consolidating positions after the company's November 5 Q3 2026 earnings report (which raised full-year 2026 guidance for a third time) and amid investor caution around 2027 expansion execution and healthcare costs. Source: FMP price data; BestStocks detection.
Oscar Health, Inc. (OSCR) moved -7.58% from $29.83 to $27.57 on November 18, 2026, reaching a new 30-day low on modestly elevated volume (1.7x the 5-day average). The pullback followed a steep year-to-date run-up of roughly 95%–108% and occurred despite no major negative company announcement on the day itself. Profit-taking appears to have intensified after the stock slipped below its 50-day moving average earlier in November, with traders consolidating positions after the company's November 5 Q3 2026 earnings report (which raised full-year 2026 guidance for a third time) and amid investor caution around 2027 expansion execution and healthcare costs.
What to watch next: Oscar Health is scheduled to report Q4 2026 earnings on February 9, 2027 (consensus EPS estimate: −$1.08); watch for any updates on 2027 expansion progress and medical cost guidance.
Earlier sessions that moved OSCR
- −4.8%Oscar Health filed a material event 8-K today, triggering a 3.18% decline to $30.34.
- −2.8%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −4.1%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +4.1%After the company integrated HealthEx's medical records connectivity into its app for new members from day one.
- +4.9%After the company raised its full-year operating earnings outlook for the third time following a profitable Q3, citing membership growth and a $250M risk-adjustment benefit.
- −7.6%A material event filing (8-K) was also submitted today.
- −5.7%Despite reporting Q3 2026 EPS of $0.49, which beat the consensus loss estimate of $0.14 by $0.60 per share.
- +4.5%Ahead of its earnings announcement scheduled for 2026-11-05.
- −2.8%We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −7.0%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +3.4%After announcing its expansion into South Carolina, bringing its footprint to 713 counties across 21 states by 2027.
- −4.7%OSCR moved -4.82% from its $33.51 open to a $31.89 close on 2026-10-16.
- +4.8%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +3.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −3.0%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Oscar Health, Inc. (OSCR) shares tumbled 7.6% to $27.57 as of November 19, 2026, a significant decline from the prior close of $29.84. BestStocks flagged the session as a major change for OSCR. The move is tied to price move down. Below, we break down what changed for OSCR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
OSCR fell 7.6% to $27.57
OSCR tumbled 7.6% in its latest session, moving from $29.84 to $27.57.
What it means for Oscar Health, Inc. investors
For Oscar Health, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Oscar Health beat Q3 2026 earnings and revenue estimates and raised its full-year 2026 outlook, per Business Wire and Zacks; Positive price momentum. Weighing against that: Material negative event; Sharp 7.6% decline — elevated risk. Wall Street's consensus price target sits at $37.43, implying +35.8% upside from $27.57. BestStocks rates the overall signal quality medium (62/100). With earnings roughly 82 days out, the next report is the most likely near-term test of the move.
OSCR price reaction
OSCR last traded at $27.57, down $2.27 (-7.61%) from the previous close of $29.84. The session traded on 1.4× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $27.57 and $35.19, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Oscar Health, Inc. (OSCR)
The consensus analyst price target on Oscar Health, Inc. (OSCR) is $37.43, 35.8% above the recent $27.57. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 0 downgrades. Here is how the bullish and bearish cases on OSCR line up.
The bullish case
- Wall Street's consensus price target of $37.43 implies +35.8% upside from $27.57.
- The Street's most bullish target is $49.00 (+77.7%).
- Oscar Health beat Q3 2026 earnings and revenue estimates and raised its full-year 2026 outlook, per Business Wire and Zacks.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $20.00 (-27.5%).
- Material negative event.
- Sharp 7.6% decline — elevated risk.
- Oscar Health filed a material event 8-K today, triggering a 3.18% decline to $30.34.
- Oscar Health reported Q3 earnings today with strong outlook and margin gains (Zacks), yet the stock fell 6.37% to $31.07.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for OSCR
In-depth OSCR event analyses
Frequently asked questions about OSCR
Why did Oscar Health, Inc. (OSCR) stock move?
Oscar Health, Inc. (OSCR) fell 7.6% on November 18, 2026, closing at $27.57 versus $29.84 the prior session (close-to-close, from daily closes). The pullback followed a steep year-to-date run-up of roughly 95%–108% and occurred despite no major negative company announcement on the day itself. Profit-taking appears to have intensified after the stock slipped below its 50-day moving average earlier in November, with traders consolidating positions after the company's November 5 Q3 2026 earnings report (which raised full-year 2026 guidance for a third time) and amid investor caution around 2027 expansion execution and healthcare costs. Source: FMP price data; BestStocks detection.
How much did OSCR stock fall?
OSCR lost 7.61% ($2.27) versus the prior close of $29.84, last trading at $27.57 on 1.4× average volume.
When is Oscar Health, Inc.'s next earnings date?
OSCR's next earnings report is estimated for 2027-02-09 — about 82 days away.
What is the analyst price target for OSCR?
The consensus analyst price target for OSCR is $37.43, about 35.8% above the current $27.57. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 0 downgrades.
How BestStocks tracks OSCR
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for OSCR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
